Screener
Krystal Biotech, Inc. KRYS Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of goods sold | 6,323 | 5,028 |
| Research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Total operating expenses | 62,668 | 51,931 |
| Income from operations | 53,689 | 36,252 |
| Other income | ||
| Interest and other income, net | 7,753 | 7,345 |
| Income before income taxes | 61,442 | 43,597 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s total operating expenses?
- Krystal Biotech, Inc. (KRYS) reported total operating expenses of $62.67M in Q1 2026.
- How has Krystal Biotech, Inc.'s total operating expenses changed year-over-year?
- Krystal Biotech, Inc.'s total operating expenses increased by 20.7% year-over-year, from $51.93M to $62.67M.
- What is the long-term trend for Krystal Biotech, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s total operating expenses has grown at a 35.2% compound annual growth rate (CAGR), from $68.27M to $227.93M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Krystal Biotech, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude